Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-attr-cm-s1-ep2-2026a10006ha. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Clinical Comparison of V122I Genotypic Variant of Transthyretin Amyloid Cardiomyopathy With Wild-Type and Other Hereditary Variants: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/33768376/
Genetic and Clinical Features of Hereditary Transthyretin Amyloidosis: A Decade of Experience at a Japanese Referral Center https://pubmed.ncbi.nlm.nih.gov/40898332/
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant https://clinicaltrials.gov/study/NCT06563895
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podden och tillhörande omslagsbild på den här sidan tillhör
Medscape. Innehållet i podden är skapat av Medscape och inte av,
eller tillsammans med, Poddtoppen.